NEOS THERAPEUTICS, INC.
Presentation Operator MessageOperator (Operator)Thank you for holding, and good afternoon, and...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and manufacturing central nervous system (CNS) focused products. The Company markets Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate) and Adzenys-ER (amphetamine), all for the treatment of attention deficit hyperactivity disorder (ADHD). The Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) (generic Tussionex), for the treatment of cough and upper respiratory symptoms of a cold. It is also developing N-desethyloxybutynin (NT0502), for the treatment of sialorrhea in patients with neurological conditions. NT0502 is a selective anticholinergic agent that is developing an oral, treatment to reduce chronic sialorrhea in patients with neurological conditions associated with salivation and drooling.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
